Nonalcoholic Steatohepatitis with Fibrosis

• CLINICAL_TRIALS trial_result · 2026-04-15
  Clinical Trial Update: Dasatinib and Quercetin to Treat Fibrotic Non-alcoholic Fatty Liver Disease [Phase 1, Phase 2]

  A completed Phase 1/2 clinical trial evaluated the combination of dasatinib and quercetin for fibrotic non-alcoholic fatty liver disease (NA…

• CLINICAL_TRIALS research · 2026-03-31
  Clinical Trial Update: Non-invasive Tests for Non-alcoholic Steato-hepatitis [NA]

  This document reports an update on a clinical trial evaluating non-invasive tests for non-alcoholic steatohepatitis (NASH) with fibrosis, in…

• CLINICAL_TRIALS research · 2026-02-11
  Clinical Trial Update: A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis) [Phase 3]

  A Phase 3 trial (ENLIGHTEN-Fibrosis) is ongoing to evaluate the efficacy and safety of Pegozafermin in participants with metabolic dysfuncti…

• CLINICAL_TRIALS research · 2024-05-14
  Clinical Trial Update: Effectiveness of Bariatric Surgery for NAFLD/NASH

  A clinical trial from Beijing Friendship Hospital is assessing the effectiveness of bariatric surgery for non-alcoholic fatty liver disease …

• CLINICAL_TRIALS trial_result · 2022-03-23
  Clinical Trial Update: Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH) [Phase 3]

  Phase 3 trial of elafibranor vs placebo in nonalcoholic steatohepatitis with fibrosis was terminated; results posted in 2022.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2020-02-13
  Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of JKB-122 in Patients With NASH and Fibrosis [Phase 2]

  Phase 2 trial update for JKB-122 in nonalcoholic steatohepatitis with fibrosis to evaluate efficacy and safety.